AM-5992
/ Amgen
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 11, 2025
A Breast Cancer Prognostic Model Based on Folic Acid Metabolism-Related Genes to Reveal the Immune Landscape.
(PubMed, Horm Metab Res)
- "AM-5992 and 5-fluorodeoxyuridine 10mer may be potential BC drugs. This FMR-based model can accurately predict BC prognosis, offering a clinical reference."
Biomarker • Journal • Breast Cancer • Oncology • Solid Tumor • Women's Health • BRCA • IFNG • NFKB2 • SERPINA3
March 30, 2023
FERMT1 Is a Prognostic Marker Involved in Immune Infiltration of Pancreatic Adenocarcinoma Correlating with mA Modification and Necroptosis.
(PubMed, Genes (Basel))
- "Finally, FERMT1 overexpression may be sensitive to chemotherapy drugs such as Palbociclib, AM-5992 and TAE-226. FERMT1 can serve as a diagnostic and prognostic marker of PAAD, which is connected with immune cell infiltration and the modulation of mA and necroptosis."
Biomarker • Journal • Gastrointestinal Cancer • Hepatology • Immune Modulation • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • FERMT1
1 to 2
Of
2
Go to page
1